Coste AT Kritikos A Li J Khanna N Goldenberger D Garzoni C Zehnder C Boggian K Neofytos D Riat A Bachmann D Sanglard D Lamoth F 2020 Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%. application/pdf https://sonar.ch/global/documents/34467 eng info:eu-repo/semantics/altIdentifier/doi/10.1007/s15010-020-01475-8 info:eu-repo/semantics/altIdentifier/pmid/32661647 info:eu-repo/semantics/openAccess Infection. - 2020 Microbiology (medical) Infectious Diseases General Medicine Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland. http://purl.org/coar/resource_type/c_6501